Junichi Nezu

Gotenba, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Selective blockade of latent TGF-β1 activation suppresses tissue fibrosis with good safety.

Selective blockade of latent TGF-β1 activation suppresses tissue fibrosis with good safety.

Journal: Communications medicine

Published: December 02, 2024

Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac disease.

Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac disease.

Journal: Nature communications

Published: October 02, 2023

Complement Activation by an Anti-Dengue/Zika Antibody with Impaired Fcγ Receptor Binding Provides Strong Efficacy and Abrogates Risk of Antibody-Dependent Enhancement.

Complement Activation by an Anti-Dengue/Zika Antibody with Impaired Fcγ Receptor Binding Provides Strong Efficacy and Abrogates Risk of Antibody-Dependent Enhancement.

Journal: Antibodies (Basel, Switzerland)

Published: March 10, 2023

Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering.

Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering.

Journal: mAbs

Published: April 28, 2022

Novel myostatin-specific antibody enhances muscle strength in muscle disease models.

Novel myostatin-specific antibody enhances muscle strength in muscle disease models.

Journal: Scientific reports

Published: November 26, 2020

Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.

Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.

Journal: PloS one

Published: September 10, 2018

Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974.

Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974.

Journal: Methods (San Diego, Calif.)

Published: July 31, 2018

Corrigendum: Entire CD3ε, δ, and γ humanized mouse to evaluate human CD3-mediated therapeutics.

Corrigendum: Entire CD3ε, δ, and γ humanized mouse to evaluate human CD3-mediated therapeutics.

Journal: Scientific reports

Published: March 20, 2018

SKY59, A Novel Recycling Antibody for Complement-mediated Diseases.

SKY59, A Novel Recycling Antibody for Complement-mediated Diseases.

Journal: Current medicinal chemistry

Published: February 16, 2018

Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human.

Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human.

Journal: Drug metabolism and pharmacokinetics

Published: January 26, 2017

Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.

Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.

Journal: Scientific reports

Published: December 21, 2016

An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.

An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.

Journal: Science translational medicine

Published: November 26, 2016

Showing 1-12 of 15

Last Updated: 09/26/2026